Andrew Bellinger - Sep 23, 2022 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
CSO & CMO
Signature
/s/ Andrew Ashe, Attorney-in-Fact for Andrew Bellinger
Stock symbol
VERV
Transactions as of
Sep 23, 2022
Transactions value $
-$2,031,592
Form type
4
Date filed
9/27/2022, 05:00 PM
Previous filing
Jul 22, 2022
Next filing
Nov 1, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $29.6K +20K +301.7% $1.48* 26.6K Sep 23, 2022 Direct
transaction VERV Common Stock Sale -$230K -6.63K -24.91% $34.67 20K Sep 23, 2022 Direct F1, F2
transaction VERV Common Stock Sale -$476K -13.4K -66.85% $35.59 6.63K Sep 23, 2022 Direct F1, F3
transaction VERV Common Stock Options Exercise $59.2K +40K +603.41% $1.48* 46.6K Sep 23, 2022 Direct
transaction VERV Common Stock Sale -$1.3M -36.8K -78.92% $35.31 9.83K Sep 23, 2022 Direct F1, F4
transaction VERV Common Stock Sale -$115K -3.2K -32.57% $36.03 6.63K Sep 23, 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -40K -29.2% $0.00 97K Sep 23, 2022 Common Stock 40K $1.48 Direct F6
transaction VERV Stock Option (right to buy) Options Exercise $0 -20K -46.3% $0.00 23.2K Sep 23, 2022 Common Stock 20K $1.48 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.24 to $35.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), and (5) of this Form 4.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.26 to $36.15, inclusive.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.88, inclusive.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.92 to $36.15, inclusive.
F6 The remaining shares underlying this option, which was granted on September 17, 2019, vest in equal monthly installments until October 1, 2023.